GIVN Given Imaging Ltd. - Ordinary Shares (MM)

Given Imaging Ltd. (NASDAQ: GIVN), a world leader in GI medical devices and pioneer of capsule endoscopy, today announced two new studies highlighting the value of ManoScan High Resolution Manometry in determining the source of dysphagia in patients who have undergone anti-reflux surgery. The studies were conducted at the Hospital Clinico San Carlos in Madrid, Spain and presented at the United European Gastroenterology Week (UEGW), Europe's largest gastroenterology conference, being held in Stockholm, Sweden from October 22nd through October 26th. Given Imaging is exhibiting at booth A08:30 throughout the conference.

"The cause of dysphagia post-fundoplication has previously been very difficult to determine and treat. Our data suggest that the use of high resolution manometry in combination with traditional diagnostic tests is extremely valuable," said Dr. Ruiz de Léon, Hospital Clinico San Carlos, Madrid, Spain. "High resolution manometry allows us to easily interpret radiological data and provides us with additional information to identify the source of dysphagia so we can appropriately treat our patients."

In a new study (abstract P0791), researchers from the Hospital Clinico San Carlos evaluated the high resolution manometry (HRM) findings of 30 patients with long-term dysphagia after Nissen fundoplication. All patients underwent HRM, barium x-ray, esophageal endoscopy and ambulatory pH monitoring, and the results of the four tests were compared to look for possible mechanisms of dysphagia post-surgery. The study authors concluded high resolution manometry accurately located the lower esophageal sphincter and esophagogastric junction allowing the researchers to identify the source of dysphagia. In addition, HRM was able to show dysfunctional fundoplication indicated by pressure abnormalities at the gastric level and mechanism changes difficult to diagnose by other modalities. Overall the authors found that HRM complements the traditional techniques and makes interpretation of clinical results easier.

Using the same patient population, the study authors compared the clinical value of ManoScan High Resolution Manometry to radiology, endoscopy, and pH monitoring in poster presentation, P0792. The cause of dysphagia was identified in 18 of 30 patients, in the remaining 12 patients, 10 cases of probable but less specific causes for dysphagia were found, the final two cases were inconclusive. The results of HRM testing identified 21 patients with abnormal findings. The study authors concluded that all four diagnostic tests are complementary for dysphagia post-fundoplication. However, high resolution manometry alone was superior to all other tests and one of the most useful techniques for diagnosing post-Nissen dysphagia.

About Esophageal Dysphagia Dysphagia, also known as difficulty swallowing, results from impeded transport of liquids, solids, or both from the pharynx to the stomach.(1) Although dysphagia can happen to anyone, it is most common in older adults, premature babies, and people with problems of the brain or nervous system.(2) Normally, the muscles in esophagus squeeze, or contract, to move food and liquids from the mouth to the stomach without problem. However when there is an obstruction in the esophagus or the muscles and nerves that help move food through the throat and esophagus are not working right patients can experience difficulty or the inability to swallow. Dysphagia in adults may be due to tumors, conditions that cause the esophagus to narrow, neuromuscular conditions, stroke, GERD or when the muscles in the esophagus do not relax enough to let food pass to the stomach.(3) Other risk factors include smoking, excessive alcohol use, certain medications, and teeth or dentures in poor condition. Treatment for dysphagia can range from esophageal exercises, medication and in severe cases surgery to clear or repair the esophagus.(4)

About ManoScan ESO ManoScan™ pioneered solid state high resolution manometry (HRM) and remains the market leader in comprehensive solutions for assessing gastrointestinal motility. Through the combination of proprietary tactile-sensing catheter technology and easy-to-use ManoView™ software, ManoScan reveals complex functional anatomy, enabling physicians to more accurately diagnose abnormalities of the gastrointestinal tract.

All medical procedures carry some risks. The risks of catheter insertion into the nasal passage include: discomfort, nasal pain, minor bleeding, runny nose, throat discomfort, irregular heartbeat with dizziness, and perforation. In rare instances, the catheter may be misdirected into the trachea causing coughing or choking, or the catheter may shift up or down causing false results. Medical, endoscopic, or surgical intervention may be necessary to address any of these complications, should they occur. The system is not compatible for use in an MRI magnetic field.

About Given Imaging Ltd. Since pioneering the field of capsule endoscopy in 2001, Given Imaging has become a world leader in GI medical devices, offering health care providers a range of innovative options for visualizing, diagnosing and monitoring the digestive system. The company offers a broad product portfolio including PillCam® video capsules for the small bowel, esophagus and colon [PillCam® COLON not approved for use in the United States.], industry-leading ManoScan™ high-resolution manometry and Bravo® wireless and Digitrapper® pH and impedance products. Given Imaging is committed to delivering breakthrough innovations to the GI community and supporting its ongoing clinical needs. Given Imaging's headquarters are located in Yoqneam, Israel, with operating subsidiaries in the United States, Germany, France, Japan, Australia, Vietnam and Hong Kong. For more information, please visit www.givenimaging.com.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, projections about our business and our future revenues, expenses and profitability. Forward-looking statements may be, but are not necessarily, identified by the use of forward-looking terminology such as "may," "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual events, results, performance, circumstances or achievements of the Company to be materially different from any future events, results, performance, circumstances or achievements expressed or implied by such forward-looking statements. Factors that could cause actual events, results, performance, circumstances or achievements to differ from such forward-looking statements include, but are not limited to, the following: (1) our ability to develop and bring to market new products, (2) our ability to successfully complete any necessary or required clinical studies with our products, (3) our ability to receive regulatory clearance or approval to market our products or changes in regulatory environment, (4) our success in implementing our sales, marketing and manufacturing plans, (5) the level of adoption of our products by medical practitioners, (6) the emergence of other products that may make our products obsolete, (7) lack of an appropriate bowel preparation materials to be used with our PillCam COLON capsule, (8) protection and validity of patents and other intellectual property rights, (9) the impact of currency exchange rates, (10) the effect of competition by other companies, (11) the outcome of significant litigation, (12) our ability to obtain reimbursement for our product from government and commercial payors, (13) quarterly variations in operating results, (14) the possibility of armed conflict or civil or military unrest in Israel, (15) the impact of global economic conditions, (16) our ability to successfully integrate acquired businesses, (17) changes and reforms in applicable healthcare laws and regulations, (18) product quality issues that could require us to recall products and impact our sales, and (19) other risks and factors disclosed in our filings with the U.S. Securities and Exchange Commission, including, but not limited to, risks and factors identified under such headings as "Risk Factors," "Cautionary Language Regarding Forward-Looking Statements" and "Operating Results and Financial Review and Prospects" in the Company's Annual Report on Form 20-F for the year ended December 31, 2010. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except for the Company's ongoing obligations to disclose material information under the applicable securities laws, it undertakes no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.

(1) Merck Manual. Dysphagia. http://www.merckmanuals.com/professional/gastrointestinal_disorders/esophageal_and_swallowing_disorders/dysphagia.html (2) WebMD. http://www.webmd.com/digestive-disorders/tc/difficulty-swallowing-dysphagia-overview (3) University of Maryland Medical Center. http://www.umm.edu/altmed/articles/dysphagia-000053.htm (4) Mayo Clinic. http://www.mayoclinic.com/health/difficulty-swallowing/DS00523/DSECTION=treatments-and-drugs

For further information contact: Fern Lazar/David Carey Lazar Partners Ltd. 1-212-867-1768 flazar@lazarpartners.com dcarey@lazarpartners.com